川芎嗪合生脉注射液治疗急性发作期肺心病的研究  

Study of ligustrazine and Shengmai injection on pulmonary heart disease in acute stage

作　　者：郑洁[1] 

机构地区：[1]江西省中医院,江西南昌330006

出　　处：《现代中西医结合杂志》2004年第4期431-432,共2页Modern Journal of Integrated Traditional Chinese and Western Medicine

摘　　要：目的　观察川芎嗪合生脉注射液治疗急性发作期肺心病的疗效。方法　将 6 3例患者随机分为 2组 ,治疗组 33例采用静脉滴注川芎嗪和生脉注射液并配合西医常规治疗 ,对照组 30例则单用西医常规治疗 ,观察两组疗效。结果　治疗组总有效率为 94 % ,对照组为 90 % ,两组比较无显著性差异 (P >0 .0 5 ) ,但治疗组显效率明显高于对照组 ,有显著性差异 (P <0 0 5 ) ;两组治疗后血气分析、血流变学指标比较 ,治疗组优于对照组。结论　川芎嗪和生脉注射液结合西医常规治疗急性发作期肺心病可明显提高疗效。Objective It is to observe the clinical effect of ligustrazine and Shengmai injection on pulmonary heart disease in acute stage. Methods Sixty-three patients were divided into two groups at random. Thirty-three patients in treatment group were treated with ligustrazine and Shengmai injection combined with routine western medicine therapy, while the thirty patients in control group were treated only with routine western medicine therapy. Results The total effective rates in treatment group and control group respectively were 94% and 90%, there was no significant difference (P>0.05). The marked effective rate in the treatment group was significantly higher than that in control group and the there was significant difference (P<0.05). The blood gas analysis and blood rheology indexes in the treatment group were superior to those in the control group. Conclusion Intravenous ligustrazine and Shengmai injection combined with routine western medicine has higher curative effect on pulmonary heart disease in acute stage.

关 键 词：川芎嗪 生脉注射液 肺源性心脏病 

分 类 号：R541.5[医药卫生—心血管疾病]